bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma Read more about bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors Read more about bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors
bluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121 Read more about bluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121
bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting Read more about bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting
bluebird bio to Present at Investor Conferences in September Read more about bluebird bio to Present at Investor Conferences in September
bluebird bio to Present at Wedbush PacGrow Healthcare Conference Read more about bluebird bio to Present at Wedbush PacGrow Healthcare Conference
bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress
2017 Wedbush PacGrow Healthcare Conference Read more about 2017 Wedbush PacGrow Healthcare Conference
bluebird bio Announces Pricing of Public Offering of Common Stock Read more about bluebird bio Announces Pricing of Public Offering of Common Stock
bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD) Read more about bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD)